Cargando…

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir

We conducted a clinical study to determine the effect of efavirenz and ritonavir on the pharmacokinetics of R‐ and S‐PZQ in healthy male participants. This was toward evaluating the risk of drug‐drug interactions, which may occur after PZQ administration to HIV patients on efavirenz or ritonavir con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutiti, Chenai Sheilla, Kapungu, Nyasha Nicole, Kanji, Comfort Ropafadzo, Stadler, Nadina, Stingl, Julia, Nhachi, Charles, Hakim, James, Masimirembwa, Collen, Thelingwani, Roslyn Stella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085964/ https://www.ncbi.nlm.nih.gov/pubmed/33929078 http://dx.doi.org/10.1002/prp2.769

Ejemplares similares

In vitro and in vivo human metabolism and pharmacokinetics of S‐ and R‐praziquantel
por: Kapungu, Nyasha Nicole, et al.
Publicado: (2020)

Analytical validation of GenoPharm a clinical genotyping open array panel of 46 pharmacogenes inclusive of variants unique to people of African ancestry
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

Healthcare Professionals’ Knowledge of Pharmacogenetics and Attitudes Towards Antimicrobial Utilization in Zambia: Implications for a Precision Medicine Approach to Reducing Antimicrobial Resistance
por: Mufwambi, Webrod, et al.
Publicado: (2021)

Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers
por: Li, Xue-Qing, et al.
Publicado: (2021)

The cytotoxicity study of praziquantel enantiomers
por: Sun, Qian, et al.
Publicado: (2016)

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
por: Dhoro, Milcah, et al.
Publicado: (2015)

CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy
por: Langmia, Immaculate M., et al.
Publicado: (2021)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
por: Kovač, Jana, et al.
Publicado: (2017)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects
por: Matimba, Alice, et al.
Publicado: (2009)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Development of Praziquantel sulphonamide derivatives as antischistosomal drugs
por: Angeli, Andrea, et al.
Publicado: (2022)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Community burden of undiagnosed HIV infection among adolescents in Zimbabwe following primary healthcare-based provider-initiated HIV testing and counselling: A cross-sectional survey
por: Simms, Victoria, et al.
Publicado: (2017)

Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine
por: Taylor, Alexander B., et al.
Publicado: (2015)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
por: Alomar, Fadhel A., et al.
Publicado: (2022)

Simulation of metabolism-based herb-drug interaction: towards safe and efficacious use of NIPRD-AM1
por: Adzu, Bulus, et al.
Publicado: (2013)

Giant annular lichenoid drug eruption caused by efavirenz therapy
por: Baumrin, Emily, et al.
Publicado: (2018)

The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy
por: Chiou, Pey-Tsyr, et al.
Publicado: (2021)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes
por: Muyambo, Sarudzai, et al.
Publicado: (2022)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Preparative Scale Resolution of Enantiomers Enables Accelerated Drug Discovery and Development
por: Leek, Hanna, et al.
Publicado: (2017)

Praziquantel–Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug
por: Borrego-Sánchez, Ana, et al.
Publicado: (2020)

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
por: Svedmyr, Anders, et al.
Publicado: (2022)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug—Efavirenz
por: Jenita, Josephine Leno, et al.
Publicado: (2014)

A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics
por: Soko, Nyarai D., et al.
Publicado: (2018)

Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy
por: Florio, Rosalba, et al.
Publicado: (2021)

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
por: Liptrott, Neill J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jm2v3osngg5p9la9pdmj9tjgnr